FT-516

N/A

Report date: 2026/02/18 20:02:09

Base Information

Drug NameFT-516
Drug Alias NameFT-516 iPSC-derived Natural Killer (NK) cellhnCD16 engineered iPSC-derived NK cell therapyFT-516
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cell replacementsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsFCGR3A (CD16a) NK-cell engagers
TargetsLow affinity immunoglobulin gamma Fc region receptor III-A
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursFallopian Tube Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of MinnesotaFate Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMasonic Cancer Center, University Of Minnesota
Inactive CompaniesFate Therapeutics Inc
Active IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsAbdominal Neoplasms
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursLymphoma, B-Cell +[4] 

Other Information

ATC CodeN/A
Related LinksN/A